Verona Pharma plc (VRNA)
Oct 7, 2025 - VRNA was delisted (reason: acquired by MRK)
106.91
+0.12 (0.11%)
Inactive · Last trade price on Oct 6, 2025

Verona Pharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-81.19-173.42-54.37-68.7-55.57-65.15
Depreciation & Amortization
1.111.060.680.640.630.62
Other Amortization
2.371.30.120.080.110.01
Asset Writedown & Restructuring Costs
-----0.29
Stock-Based Compensation
93.6841.2419.0114.1225.4322.18
Other Operating Activities
9.8713.35-1.764.74-17.3-0.92
Change in Accounts Receivable
-82.86-31.5----
Change in Inventory
-14.52-8.22----
Change in Accounts Payable
-0.727.870.49-7.159.87-1.4
Change in Income Taxes
-1.8714.68-2.144.1-6.780.77
Change in Other Net Operating Assets
1.6311.43-12.24-7.6910.36-1.48
Operating Cash Flow
-72.49-122.2-50.22-59.86-33.25-45.08
Capital Expenditures
-1.07-0.58--0.03-0.01-0.08
Investment in Securities
-----9.79
Investing Cash Flow
-1.07-0.58--0.03-0.019.71
Long-Term Debt Issued
-122.538.7110-5
Long-Term Debt Repaid
--52.26--5.85--
Net Debt Issued (Repaid)
122.570.2438.714.15-5
Issuance of Common Stock
112.2102.958.86151.170.73200.2
Repurchase of Common Stock
-124.61-15.45-4.69-4.72-6.85-
Other Financing Activities
-4.6193.09-0.01-9.78--12.86
Financing Cash Flow
105.47250.7892.87140.82-6.12192.34
Foreign Exchange Rate Adjustments
1.51-0.011.3-1.48-0.220.58
Net Cash Flow
33.42127.9943.9579.45-39.61157.56
Free Cash Flow
-73.56-122.78-50.22-59.89-33.27-45.16
Free Cash Flow Margin
-33.18%-290.41%--13076.64%-83.17%-
Free Cash Flow Per Share
-0.88-1.51-0.63-0.91-0.56-1.37
Cash Interest Paid
24.7110.332.010.350.220.01
Cash Income Tax Paid
9.820.641.250.1200.01
Levered Free Cash Flow
-57.39-68.93-36.63-34.752.1-18.4
Unlevered Free Cash Flow
-36.5-55.52-35.46-34.52.19-18.39
Change in Working Capital
-98.34-5.74-13.9-10.7413.44-2.11
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q